Webinar: Three Key Considerations When Implementing AI in Drug Discovery
The webinar, led by Haydn Boehm, focuses on three key considerations—reasonable expectations, clean data, and collaboration—for successfully implementing AI in small molecule drug discovery amidst the current hype and ongoing preclinical development of AI-native candidates.
Despite the buzz around artificial intelligence (AI), most industry insiders know that the use of machine learning (ML) in drug discovery is nothing new. For more than a decade, researchers have used computational techniques for many purposes, such as finding hits, modeling drug-protein interactions, and predicting reaction rates.
What is new is the hype. As AI has taken off in other industries, countless start-ups have emerged promising to transform drug discovery and design with AI-based technologies. While a few “AI-native” candidates are in clinical trials, around 90% remain in discovery or preclinical development, so it will take years to see if the bets pay off. This begs the question: Is AI for drug discovery more hype than hope? Absolutely not. Do we need to adjust our expectations and position for success? Absolutely, yes.
In this webinar, we will discuss the keys to successfully implement AI in small molecule drug discovery:
- Reasonable expectations
- Clean data
- Collaboration
Featured Speaker
Haydn Boehm
Haydn is focused on helping the life science and drug discovery industries learn how to harmonize their science and data, and accelerate innovation to make the world a healthier, cleaner, better place to live. Haydn has 20 years sales and marketing leadership experience in the life science industry working with companies such as ThermoFisher Scientific, Johnson Matthey and more recently with Merck KGaA’s Connected Lab Program. Haydn has a PhD in Organic Chemistry from the University of Nottingham, UK, and lives on the Jurassic Coast in Devon, UK with his family.
Event Details
- Date: October 6, 2022
- Time: 8:00am PDT
- Location: Online
Related
Reasonable Expectations, Clean Data, Collaboration: The Three Keys to AI in Drug Discovery
The article explains that while AI and machine learning have long been used in drug discovery, recent hype and massive investments have led to unrealistic expectations, emphasizing that success depends on setting reasonable goals, ensuring clean and abundant data, and fostering collaboration, as most AI-driven drug candidates remain in early development stages and face complex biological and practical challenges.
Data Evolution in Pharma: The Spread of Multimodal
The pharmaceutical industry is shifting from single-mode to multimodal drug discovery, incorporating diverse therapeutic modalities like biologics, gene therapies, and small molecules, but this evolution presents significant challenges in integrating heterogeneous R&D data and technologies, necessitating advanced, compatible platforms to enable efficient collaboration and leverage AI-driven insights for faster, cost-effective drug development.
CBS News: How AI Is Accelerating Safer, More Personalized Drug Discovery
In a CBS News interview, Dotmatics VP Phil Mounteney explains how their internally developed AI models accelerate drug discovery by analyzing early-phase research data to shorten development cycles, reduce costs, and deliver safer, personalized therapies while maintaining data privacy.
Lessons Learned for AI in Small Molecule Drug Discovery
The article discusses the longstanding use of machine learning in small molecule drug discovery, highlights the recent surge of AI-driven start-ups amid industry hype, and emphasizes the need to temper expectations by learning from past technology challenges and other industries to successfully implement AI in drug discovery.
Webinar: Are you Ready for the Renaissance in Small Molecule Drug Discovery?
The webinar titled "Are you Ready for the Renaissance in Small Molecule Drug Discovery?" scheduled for February 2, 2023, features expert Haydn Boehm discussing challenges in small molecule drug discovery, emphasizing the importance of research collaboration, efficient data integration from multiple sources, and workflow optimization to reduce costs and accelerate finding better therapeutic candidates.
The Rise of Biotech: Why Smaller Companies Are Outpacing Big Pharma on Innovation
Smaller biotech companies are increasingly outpacing big pharmaceutical firms in new molecular entity approvals due to their greater agility, willingness to take risks, and freedom to innovate despite funding challenges, with over half of upcoming blockbuster drug launches expected from first-time launchers who face higher risks but also potential for significant success.